Michael Leiter

Electromed Names Jim Cunniff as President and Chief Executive Officer

Retrieved on: 
Monday, June 5, 2023
General Health, Health, Medical Supplies, Medical Devices, Chairperson, Senior, Marketing, Ruane, Cunniff & Goldfarb, Stryker Corporation, Emerging market, Patient, Growth, NYSE, Medtech, Michael Leiter, Chair, Kinetics, Management, Electromation Inc

Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023.

Key Points: 
  • Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023.
  • “We are pleased to announce the appointment of Jim Cunniff as president and CEO,” said Lee Jones, Chair of the Board.
  • Previously, Cunniff was the President, Chief Executive Officer, and Board Director for Leiters, the Senior Vice President of Americas for Kinetics Concepts, and the President of Emerging Markets for Stryker Corporation.
  • “I am thrilled that Jim Cunniff will be my successor as President and Chief Executive Officer of Electromed and look forward to working with him as I transition to the Chair role,” said Kathleen Skarvan, longtime Chief Executive Officer of Electromed.

Leiters and EyeConnect International Announce Continued Corporate Partnership

Retrieved on: 
Wednesday, February 1, 2023
FDA, ASCRS, Senior, Health, ECI, Cataract, Refractive surgery, Ophthalmology, American Society of Cataract and Refractive Surgery, Michael Leiter, Patient, Partnership, Pharmaceutical industry, Nursing

DENVER, Feb. 1, 2023 /PRNewswire/ -- Leiters, a trusted FDA-registered 503B outsourcing provider of compounded sterile preparations and pharmacy services, announced today that it has renewed its corporate partnership with EyeConnect International (ECI) in support of their digital ophthalmic clinical knowledge-sharing platform for ophthalmologists world-wide.

Key Points: 
  • DENVER, Feb. 1, 2023 /PRNewswire/ -- Leiters, a trusted FDA-registered 503B outsourcing provider of compounded sterile preparations and pharmacy services, announced today that it has renewed its corporate partnership with EyeConnect International (ECI) in support of their digital ophthalmic clinical knowledge-sharing platform for ophthalmologists world-wide.
  • "We are honored that Leiters recognizes the value of peer-to-peer education," said David Karcher, Board Member, EyeConnect International and former Executive Director, American Society of Cataract and Refractive Surgery (ASCRS).
  • "Partnering with EyeConnect International extends our commitment to ophthalmologists, health care systems, and their patients," said Timothy Askew, Senior Vice President and General Manager for Leiters.
  • "We are delighted to announce this partnership and look forward to collaborating with EyeConnect International on new and innovative ways to extend the reach of their global knowledge-sharing platform."

Joseph C. Cosgrove Appointed as President and Chief Executive Officer of Leiters

Retrieved on: 
Tuesday, January 24, 2023
Novant Health, Culture, UNC Health Care, Partnership, FDA, Growth, Mayo Clinic, Patient, Michael Leiter, Pharmaceutical industry, Management

DENVER, Jan. 24, 2023 /PRNewswire/ -- Leiters, a trusted FDA-registered 503B outsourcing provider of compounded sterile preparations and pharmacy services, announced today that it has appointed Joseph C. Cosgrove as President, Chief Executive Officer, and Director of the Company.

Key Points: 
  • DENVER, Jan. 24, 2023 /PRNewswire/ -- Leiters, a trusted FDA-registered 503B outsourcing provider of compounded sterile preparations and pharmacy services, announced today that it has appointed Joseph C. Cosgrove as President, Chief Executive Officer, and Director of the Company.
  • Mr. Cosgrove joined Leiters on January 16, 2023 and will be based out of the company's offices in Denver, Colorado.
  • For the past fifteen years, he served as Chairman, President, and Chief Executive Officer for Pentec Health.
  • "Leiters has been heralded as one of the leading FDA-registered 503B outsourcing providers of compounded sterile preparations for many years.

H.I.G. Capital Completes Acquisition of Celerion

Retrieved on: 
Thursday, November 3, 2022
Banking, Research, General Health, Professional Services, Pharmaceutical, Other Manufacturing, Clinical Trials, Science, Biotechnology, Finance, Health, Other Science, Manufacturing, Company, Growth, Investment, Biotechnology, Whitehorse, CLO, Industry, BDC, Data management, Paulo, Cros, Organization, Winston & Strawn, Clinical trial, Taconic Biosciences, McDermott Will & Emery, Drug development, Rothschild, Acquisition, H.I.G. Capital, United Kingdom, Financial services, Fine chemical, Pharmaceutical industry, Michael Leiter

), a leading global investment firm with $52 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Celerion Holdings, Inc. (Celerion or the Company), a leading full-service provider of outsourced clinical research services to the pharmaceutical industry.

Key Points: 
  • ), a leading global investment firm with $52 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Celerion Holdings, Inc. (Celerion or the Company), a leading full-service provider of outsourced clinical research services to the pharmaceutical industry.
  • Celerion has locations in the United States, Canada, Austria, South Korea, Switzerland, and the United Kingdom.
  • Susan Thornton, Ph.D., Chief Executive Officer of Celerion commented, We are excited to enter into this new chapter of growth with H.I.G.
  • We believe Celerion is well-positioned for continued growth, given its dedication to the most rigorous quality and performance standards.

Leiters, a WCAS Portfolio Company, Joins the End Drug Shortages Alliance

Retrieved on: 
Wednesday, June 29, 2022
Health, FDA, East End Drugs, Patient, CEO, CGMP, Good manufacturing practice, FD, Evolutionary models of human drug use, Industry, Mayo Clinic, Organization, Quality of life, Alliance, IV, Hospital, Medical device, Pharmaceutical industry, Michael Leiter

The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care's more pressing and enduring issues, drug shortages that disrupt patient care.

Key Points: 
  • The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care's more pressing and enduring issues, drug shortages that disrupt patient care.
  • "Drug shortages impact the delivery of critical medicines and the delivery of patient care," said Robin Smith Hoke, President and CEO of Leiters.
  • "As a member of the alliance, we will work collaboratively across the supply chain to develop strategies to address factors that contribute to these shortages."
  • The End Drug Shortages Alliance was launched in late 2021 to bring together industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors and other industry thought leaders and champions.

Leiters Announces Facility Acquisition to Increase Capacity, Accommodate Growth and Expand Portfolio

Retrieved on: 
Tuesday, February 8, 2022
Medicine, Investment, Company, Evolutionary models of human drug use, Ophthalmology, Welsh, General partnership, FDA, Patient, Compliance, CGMP, FD, CEO, Welsh, Carson, Anderson & Stowe, Good manufacturing practice, R, Acquisition, Pharmaceutical industry, Michael Leiter

The 110,000 square foot facility was previously used to manufacture prescription products, including sterile preparations.

Key Points: 
  • The 110,000 square foot facility was previously used to manufacture prescription products, including sterile preparations.
  • The former pharmaceutical company owner made considerable capital investments to expand and upgrade the facility, including manufacturing capabilities for injectables, R&D, and labs.
  • This second facility will meaningfully increase Leiters' manufacturing capacity, enable new product capabilities, and provide additional warehousing of sterile compounded preparations for the 503B market.
  • Leiters combines a highly experienced team, with robust automated processes, in a state-of-the-art outsourcing facility, to ensure delivery of the highest quality medicines.

H.I.G. Capital Completes Strategic Investment in Rising Pharmaceuticals

Retrieved on: 
Monday, December 13, 2021
Other Manufacturing, Other Consumer, Finance, Banking, Professional Services, Manufacturing, General Health, Pharmaceutical, Consumer, Health, Company, CDO, Growth, Vimal, Whitehorse, H.I.G. Capital, CMO, CLO, Paulo, Michael Leiter, Medication, CEO, Investment, BDC, Fine chemical, Financial services, Rising Pharmaceuticals, H.I.G. Capital, RISING PHARMACEUTICALS, H.I.G. CAPITAL

"), a leading global alternative investment firm with over $45 billion of equity capital under management, is pleased to announce that one of its affiliates has made a strategic equity investment into Rising Pharma Holdings and Casper Pharma (collectively, Rising Pharmaceuticals or the Company), a leading provider of generic and specialty pharmaceuticals in the United States.

Key Points: 
  • "), a leading global alternative investment firm with over $45 billion of equity capital under management, is pleased to announce that one of its affiliates has made a strategic equity investment into Rising Pharma Holdings and Casper Pharma (collectively, Rising Pharmaceuticals or the Company), a leading provider of generic and specialty pharmaceuticals in the United States.
  • With a diversified portfolio of over 125 products and the ability to quickly commercialize complex molecules, Rising Pharmaceuticals is strategically positioned in the U.S. pharmaceuticals market.
  • "We are excited to partner with Vimal Kavuru and Rising Pharmaceuticals exceptional management team," said Mike Gallagher, Managing Director at H.I.G.
  • H.I.G.s investment in Rising Pharmaceuticals represents its latest transaction in the pharma services sector.